Posology : מינונים

2     DOSAGE AND ADMINISTRATION
2.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture
The recommended dose is 20 mcg subcutaneously once a day.
2.2 Increase of Bone Mass in Men with Primary or Hypogonadal Osteoporosis at High Risk for Fracture
The recommended dose is 20 mcg subcutaneously once a day.

2.3 Treatment of Men and Women with Glucocorticoid-Induced Osteoporosis at High Risk for Fracture
The recommended dose is 20 mcg subcutaneously once a day.
2.4 Administration
• Teriparatide Kamada should be administered as a subcutaneous injection into the thigh or abdominal wall. There are no data available on the safety or efficacy of intravenous or intramuscular injection of teriparatide.
•Teriparatide Kamada should be administered initially under circumstances in which the patient can sit or lie down if symptoms of orthostatic hypotension occur [see Warnings and Precautions (5.7)].
• Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Teriparatide Kamada is a clear and colorless liquid. Do not use if solid particles appear or if the solution is cloudy or colored.
• Patients and caregivers who administer Teriparatide Kamada should receive appropriate training and instruction on the proper use of the Teriparatide Kamada delivery device from a qualified health professional.
2.5 Treatment Duration
The safety and efficacy of teriparatide have not been evaluated beyond 2 years of treatment. Consequently, use of the drug for more than 2 years during a patient’s lifetime is not recommended.